During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1. The candidate is a live replicating virus vaccine using a vaccinia virus vector.
During the COVID-19 pandemic, researchers at the OHRI created an experimental COVID-19 vaccine named TOH-Vac1. This vaccine uses a vaccinia virus as a delivery system for genetic material that triggers an immune response against the virus.